Estratab (.3 mg )

Solvay Pharmaceuticals

Approval Status
Approved March 1998

Treatment for
prevention of osteoporosis

Diabetes / Endocrinology , Musculoskeletal , Pregnancy & Gynecology

Estratab (.3 mg ) has been approved for the prevention of osteoporosis.

In a two-year clinical trial, women on .3 mg Estratab tablets showed increased bone mineral density over baseline in the spine, hip, and whole body.

Women taking this low dose also experienced fewer side effects, such as headache, nausea, breast tenderness, and vaginal bleeding, than women on higher doses.

Estratab (.3 mg ) Drug Information

The Estratab (.3 mg ) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top